Carl L. Gordon, a director at Compass Therapeutics ($CMPX), sold shares worth $5.7 million on the open market once in the past year. His most recent sale occurred on April 9, 2025. This activity ranks him 1,767th among 11,678 insiders by sales value, below the average of $8.6 million across about 6.4 transactions. He reported no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Compass Therapeutics, Inc. | $CMPX | GORDON CARL L | Director | A | Stock Option (Right to Buy) | 90000 | $0.00 | 90,000.0000 | 177,862,102 | 9999.99% | 0.05% |
| Nov. 21, 2025 | Keros Therapeutics, Inc. | $KROS | GORDON CARL L | Director | D | Common Stock | 140057 | $17.75 | 759,155.0000 | 41,202,371 | 15.58% | 0.34% |
| Nov. 21, 2025 | Keros Therapeutics, Inc. | $KROS | GORDON CARL L | Director | D | Common Stock | 74465 | $17.75 | 45,057.0000 | 41,202,371 | 62.30% | 0.18% |
| June 4, 2025 | Keros Therapeutics, Inc. | $KROS | GORDON CARL L | Not found | A | Common Stock | 5250 | $0.00 | 1,023,984.0000 | 37,437,652 | 0.52% | 0.01% |
| June 4, 2025 | Keros Therapeutics, Inc. | $KROS | GORDON CARL L | Not found | A | Stock Option (right to buy) | 10500 | $0.00 | 10,500.0000 | 37,437,652 | 9999.99% | 0.03% |
| April 9, 2025 | Compass Therapeutics, Inc. | $CMPX | GORDON CARL L | Director | S | Common Stock | 3571428 | $1.59 | 15,219,994.0000 | 138,282,498 | 19.01% | 2.58% |
| Feb. 14, 2025 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Director | P | Common Stock | 17962 | $9.90 | 3,176,390.0000 | 0 | 0.57% | 0.00% |
| Feb. 18, 2025 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Director | P | Common Stock | 94100 | $10.84 | 747,887.0000 | 0 | 14.39% | 0.00% |
| Feb. 14, 2025 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Director | P | Common Stock | 29540 | $9.85 | 3,205,930.0000 | 0 | 0.93% | 0.00% |
| Feb. 18, 2025 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Director | P | Common Stock | 49070 | $10.84 | 3,255,000.0000 | 0 | 1.53% | 0.00% |
| Feb. 11, 2025 | Compass Therapeutics, Inc. | $CMPX | GORDON CARL L | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Not found | C | Common Stock | 403787 | $0.00 | 3,562,215.0000 | 0 | 12.78% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Not found | P | Common Stock | 500000 | $16.00 | 3,812,215.0000 | 0 | 15.10% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Not found | P | Common Stock | 250000 | $16.00 | 3,812,215.0000 | 0 | 7.02% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Not found | C | Series A Convertible Preferred Stock | 12372634 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Not found | C | Series B Convertible Preferred Stock | 19587284 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Not found | C | Series C Convertible Preferred Stock | 4854368 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Sept. 16, 2024 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Not found | C | Common Stock | 2658428 | $0.00 | 3,312,215.0000 | 0 | 406.62% | 0.00% |
| Sept. 12, 2024 | MBX Biosciences, Inc. | $MBX | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 15963 | $0.00 | 15,963.0000 | 0 | 9999.99% | 0.00% |
| Aug. 21, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | D | Stock Option (Right to Buy) | 18500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 21, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 18500 | $0.00 | 18,500.0000 | 0 | 9999.99% | 0.00% |
| Aug. 21, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | D | Stock Option (Right to Buy) | 26400 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 21, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 26400 | $0.00 | 26,400.0000 | 0 | 9999.99% | 0.00% |
| Aug. 21, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 21, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | D | Stock Option (Right to Buy) | 30000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 21, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 18500 | $0.00 | 18,500.0000 | 0 | 9999.99% | 0.00% |
| Aug. 21, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | D | Stock Option (Right to Buy) | 18500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 13, 2024 | Keros Therapeutics, Inc. | $KROS | GORDON CARL L | Director | S | Common Stock | 29400 | $44.01 | 119,522.0000 | 29,447,119 | 19.74% | 0.10% |
| Aug. 13, 2024 | Keros Therapeutics, Inc. | $KROS | GORDON CARL L | Director | S | Common Stock | 220600 | $44.01 | 899,212.0000 | 29,447,119 | 19.70% | 0.75% |
| July 16, 2024 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Director | S | Common Stock | 4009 | $10.00 | 4,839,412.0000 | 71,259,239 | 0.08% | 0.01% |
| July 16, 2024 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Director | S | Common Stock | 556 | $10.00 | 1,967,924.0000 | 71,259,239 | 0.03% | 0.00% |
| July 16, 2024 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Director | S | Common Stock | 623 | $10.00 | 755,635.0000 | 71,259,239 | 0.08% | 0.00% |
| July 15, 2024 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Director | S | Common Stock | 39433 | $10.00 | 4,843,421.0000 | 71,259,239 | 0.81% | 0.06% |
| July 15, 2024 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Director | S | Common Stock | 5401 | $10.00 | 1,968,480.0000 | 71,259,239 | 0.27% | 0.01% |
| July 15, 2024 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Director | S | Common Stock | 6142 | $10.00 | 756,258.0000 | 71,259,239 | 0.81% | 0.01% |
| July 1, 2024 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 4676 | $0.00 | 4,676.0000 | 71,259,239 | 9999.99% | 0.01% |
| June 10, 2024 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 32000 | $0.00 | 32,000.0000 | 71,259,239 | 9999.99% | 0.04% |
| June 5, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 26400 | $0.00 | 26,400.0000 | 0 | 9999.99% | 0.00% |
| June 5, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | A | Common Stock | 5900 | $0.00 | 11,458,940.0000 | 0 | 0.05% | 0.00% |
| May 30, 2024 | Keros Therapeutics, Inc. | $KROS | GORDON CARL L | Not found | A | Stock Option (right to buy) | 10000 | $0.00 | 10,000.0000 | 29,447,119 | 9999.99% | 0.03% |
| Feb. 9, 2024 | Compass Therapeutics, Inc. | $CMPX | GORDON CARL L | Director | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | C | Common Stock | 821827 | $0.00 | 821,827.0000 | 2,140,951 | 9999.99% | 38.39% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | C | Common Stock | 469615 | $0.00 | 1,291,442.0000 | 2,140,951 | 57.14% | 21.94% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | C | Common Stock | 469615 | $0.00 | 1,291,442.0000 | 2,140,951 | 57.14% | 21.94% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | P | Common Stock | 222222 | $18.00 | 1,513,664.0000 | 2,140,951 | 17.21% | 10.38% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | P | Common Stock | 222222 | $18.00 | 1,513,664.0000 | 2,140,951 | 17.21% | 10.38% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | C | Series A Preferred Stock | 821827 | $0.00 | 0.0000 | 2,140,951 | 100.00% | 38.39% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | C | Series A Preferred Stock | 821827 | $0.00 | 0.0000 | 2,140,951 | 100.00% | 38.39% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | C | Series B Preferred Stock | 469615 | $0.00 | 0.0000 | 2,140,951 | 100.00% | 21.94% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | C | Series B Preferred Stock | 469615 | $0.00 | 0.0000 | 2,140,951 | 100.00% | 21.94% |
| Jan. 30, 2024 | ArriVent BioPharma, Inc. | $AVBP | GORDON CARL L | Director | C | Common Stock | 821827 | $0.00 | 821,827.0000 | 2,140,951 | 9999.99% | 38.39% |
| Jan. 25, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | P | Common Stock | 242200 | $2.40 | 2,664,796.0000 | 0 | 10.00% | 0.00% |
| Jan. 25, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | P | Common Stock | 1041700 | $2.40 | 2,930,527.0000 | 0 | 55.15% | 0.00% |
| Jan. 25, 2024 | Adicet Bio, Inc. | $ACET | GORDON CARL L | Not found | P | Common Stock | 1841100 | $2.40 | 9,200,901.0000 | 0 | 25.02% | 0.00% |
| June 12, 2023 | Terns Pharmaceuticals, Inc. | $TERN | GORDON CARL L | Not found | A | Stock Option (Right to Buy) | 32000 | $0.00 | 32,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2023 | Keros Therapeutics, Inc. | $KROS | GORDON CARL L | Director | A | Stock Option (right to buy) | 10000 | $0.00 | 10,000.0000 | 25,241,030 | 9999.99% | 0.04% |
| Feb. 8, 2023 | Compass Therapeutics, Inc. | $CMPX | GORDON CARL L | Director | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |